orlistat

Slimming products Orlistat

Active ingredient: Orlistat is a powerful, long-lasting, specific gastrointestinal lipase inhibitor. It manifests its therapeutic activity in the lumen of the stomach and small intestine, forming a covalent link with the active serine part of gastric and pancreatic lipases. Inactivated enzyme loses the ability to hydrolyze edible fats into absorbable free fatty acids and monoglycerides. Undisseminated triglycerides are not absorbed, which leads to a reduction in calories absorbed by the body and a reduction in body weight. The therapeutic effect of the orlistate is thus performed without absorption into the systemic bloodstream. Clinical studies show that an orlistat, taken daily at a dose of 60 mg 3 times a day, blocks the absorption of about 25% of the fat in the daily diet. In addition to the reduction of body weight, a long-term administration of 60 mg of orlistate results in a decrease in the waist circumference, total cholesterol concentration and low-density lipoprotein cholesterol concentration in plasma. After 6 months of orlistatom therapy with 60 mg, the average concentration of total cholesterol in plasma decreases by an average of 2.4%, and low-density lipoprotein cholesterol - by 3.5%. The waist circumference decreases by an average of 4.5 cm after 6 months of orlist intake. Pharmacokinetics.

More info

Special instructions


Diet and exercise are an integral part of the weight loss programme. It is recommended to start a diet and exercise programme before starting Orlistat therapy. When taking Orlistat, you should follow a fractional, balanced, moderately hypocaloric diet with a fat content of no more than 30% of the daily calorie intake (e.g., with a diet of 2000 kcal/day, fat intake should be no more than 66 g/day). Recommendations on diet and physical activity should be followed, both during and after discontinuation of the drug. The use of Orlistat leads to an increase in fecal fat content 24-48 hours after the start of administration. After discontinuation of the use of Orlistat, the fat content of feces usually returns to the baseline within 48-72 hours. A diet with a low fat content reduces the likelihood of unwanted reactions from the gastrointestinal tract. Eagle intake can potentially worsen the absorption of fat-soluble vitamins (A, D, E, K and beta-carotene). In the vast majority of patients receiving an orlistat during four-year clinical trials, vitamin A, D, E, K and beta-carotene concentrations were within normal limits. For preventive purposes, it is recommended to take multivitamins overnight. Since weight loss is usually accompanied by an improvement in carbohydrate metabolism, patients with type 2 diabetes mellitus before starting, Orlistat therapy should consult a physician and, if necessary, adjust the dose of hypoglycemic drugs. A decrease in body weight during treatment may be accompanied by a decrease in blood pressure and OXs concentration in blood plasma. Patients taking hypotensive or hypolipidemic drugs should consult their physician and, if necessary, correct the dose of these drugs. Clinical studies have not observed any interaction between oral contraceptives and orlistates. However, an orlistate may indirectly reduce the bioavailability of contraceptives for ingestion, which may lead to unwanted pregnancies. Additional contraceptive methods are recommended if acute diarrhoea develops. Patients with kidney disease should consult their physician as hyperoxaluria and nephropathy may develop. Patients taking amiodarone, warfarin, or other anticoagulants for ingestion should also consult their physician before starting orlistat treatment, as changes in MMR are possible. Patients should stop taking Orlistat and seek medical advice if symptoms appear: jaundice staining of the sclera or skin, itching, darkening of the urine and loss of appetite. Eagle use has been associated with rectal bleeding. If this occurs, the patient should consult a physician. When an orlistate and sodium levothyroxine are used together, hypothyroidism and/or reduced control of hypothyroidism may occur. Patients taking sodium levothyroxin should consult their physician before starting treatment with an orlistat, as it may be necessary to take sodium orlistat and sodium levothyroxin at different times and a correction of the sodium levothyroxin dose may be necessary. Patients taking antiepileptic drugs should consult their physician before starting treatment with an orlistat, as they should be monitored for possible changes in the frequency and severity of seizures. In these cases, consideration should be given to taking orlistate and antiepileptic drugs at different times. Patients should consult their physician prior to use: the orlistate should be concurrently with antiretroviral drugs used to treat HIV infection. An orlistat can reduce the absorption of antiretroviral drugs and have a negative impact on their efficacy. Influence on the ability to drive: Orlistat does not affect the ability to drive vehicles and mechanisms.